Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 27, 2026Indian Journal of Pharmacology

Combining GLP-1 RAs and SGLT2 inhibitors reduces cardiovascular events and delays renal decline in T2D.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does the combined use of GLP-1 RAs and SGLT2 inhibitors provide cardiovascular protection in patients with type 2 diabetes?

Population

Patients with type 2 diabetes

Design

Review

Key result

Combined use of GLP-1 RAs and SGLT2 inhibitors provides complementary cardiometabolic protection in type 2 diabetes, reducing cardiovascular events and delaying renal deterioration.

Authors

SMSoumya Shanta MohantyRSR. R. SelvammathyHAHindustan Abdul Ahad

Discussion

Loading...

Member takes

Overview

Supports combined GLP-1 RA and SGLT2i use in T2D; confirms complementary cardiometabolic benefits from prior trials.

Key Points

  • This research aims to explore the combined effects of GLP-1 receptor agonists and SGLT2 inhibitors on cardiovascular health in type 2 diabetes.
  • The use of GLP-1 RAs and SGLT2 inhibitors was evaluated for their cardiometabolic benefits.
  • Clinical trials were reviewed to assess the cardiovascular events and renal function outcomes associated with these treatments.
  • GLP-1 RAs inhibit atherosclerosis and enhance blood flow through various physiological mechanisms.
  • SGLT2 inhibitors reduce cardiac preload and afterload, improving heart energy usage and increasing diuresis.
  • Both treatments associate with reduced significant cardiovascular events and prolonged renal function deterioration.

Structured PICO

Does the combined use of GLP-1 RAs and SGLT2 inhibitors provide cardiovascular protection in patients with type 2 diabetes?

P
Population
Patients with type 2 diabetes
I
Intervention
Combined use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors

The combined use of GLP-1 RAs and SGLT2 inhibitors offers complementary cardiometabolic protection in type 2 diabetes, a strategy supported by clinical guidelines.

Cite This Study

Mohanty et al. (2026) conducted a review in Type 2 diabetes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors was evaluated. Combined use of GLP-1 RAs and SGLT2 inhibitors provides complementary cardiometabolic protection in type 2 diabetes, reducing cardiovascular events and delaying renal deterioration.

synapsesocial.com/papers/6a3f6817aea7db3c1953f461https://doi.org/10.4103/ijp.ijp_1384_25
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Managing glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in clinical practice2025
  2. 2Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus?2026
  3. 3Cardiovascular Protection in Coronary Artery Disease: Mechanistic and Clinical Insights into SGLT2 Inhibitors and GLP-1 Receptor Agonists.2025
  4. 4Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs2025 · 8 citations
  5. 5Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations2026